Compare AKBA & LAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AKBA | LAW |
|---|---|---|
| Founded | 2007 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 248.3M | 286.9M |
| IPO Year | 2014 | 2021 |
| Metric | AKBA | LAW |
|---|---|---|
| Price | $0.57 | $6.06 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 3 |
| Target Price | $3.25 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 9.5M | 236.0K |
| Earning Date | 11-05-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 93.94 | 22.58 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $156,849,000.00 |
| Revenue This Year | N/A | $12.74 |
| Revenue Next Year | N/A | $10.55 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 8.29 |
| 52 Week Low | $0.36 | $2.45 |
| 52 Week High | $1.84 | $9.11 |
| Indicator | AKBA | LAW |
|---|---|---|
| Relative Strength Index (RSI) | 41.52 | 77.10 |
| Support Level | $0.54 | $3.93 |
| Resistance Level | $1.00 | $6.39 |
| Average True Range (ATR) | 0.07 | 0.29 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 45.81 | 71.57 |
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.
CS Disco Inc provides a cloud-native, artificial intelligence-powered legal solution that simplifies discovery, legal document review, and case management for enterprises, law firms, legal services providers, and governments. Its revenue-generating activities directly relate to the sale and support of legal solutions. It has two primary types of contractual arrangements: usage-based and subscription solutions. The usage-based revenue is derived from contracts under which customers are billed monthly based on their usage. Subscription revenue is derived from contracts where customers are contractually committed to a minimum data volume over a period of time.